Neuro-inflammation / Oncology
SME
Platform
Platform
Targeted protein degradation Sec61
Enodia Therapeutics is developing a proprietary small molecule platform of Sec61 inhibitors able to selectively degrade pathologic secreted and transmembrane proteins.
The site-specific blocking of Sec61 results in inhibiting the translocation of client proteins diverting them to the proteasome for cytosolic degradation.
The site-specific blocking of Sec61 results in inhibiting the translocation of client proteins diverting them to the proteasome for cytosolic degradation.
Yves Ribeill
Partner & EIR
Yves Ribeill founded Scynexis, Inc (NASDAQ: SCYX) and served as its Chairman and CEO from 1999 to 2015. Prior to Scynexis, Inc., Dr. Ribeill served various positions during the 25 years of his international career with Rhone-Poulenc, Aventis. He was involved in discovery and development effort that resulted in the FDA approval of multiple drugs. He has also been a Director of various Biotech companies in Europe and the US.